ProCE Banner Activity

Blinatumomab for MRD-Positive B-Cell Precursor ALL: An 18-Month Follow-up

Slideset Download
Conference Coverage
Patients with complete MRD response after blinatumomab treatment had prolonged OS, RFS, and DoR vs those with an incomplete MRD response.

Released: December 14, 2015

Expiration: December 12, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen